Johnson & Johnson's 4 Biggest Catalysts in 2017

Johnson & Johnson's 4 Biggest Catalysts in 2017


Though it was a very difficult year for drugmakers, with the SPDR S&P Pharmaceuticals ETF losing just shy of a quarter of its value, the same can't be said of healthcare conglomerate Johnson & Johnson , a company that leans heavily on its pharmaceutical segment for its growth and gross margin. Through Dec. 28, J&J is up a healthy 12% year to date.



from Biotech News